CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
FDA Approves Itovebi (inavolisib) for the Combination...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
Dupixent Approved in the US as the First-Ever Biologic...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.